View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 27, 2016updated 04 Jan 2022 12:27pm

MindMetre report advocates prioritisation and better funding of pathology services

UK-based consumer and business analyst MindMetre has released a new report highlighting return-on-investment from pathology services in the National Health Service (NHS) and advocating against consolidation of pathology laboratories.

UK-based consumer and business analyst MindMetre has released a new report highlighting return-on-investment from pathology services in the National Health Service (NHS) and advocating against consolidation of pathology laboratories.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

The report was carried out in response to NHS pathology review panel chairman Patrick Robert Carter’s latest report titled: 'Operational productivity and performance in English NHS acute hospitals: Unwarranted variations'.

Taking into account views of 30 laboratory managers and principal biochemists in England and Wales, the review suggested that the immediate effects of pathology service capacity and its productivity are more considerable than service funding would suggest.

It further stated that current pathology services have the potential to result in positive patient outcomes, rapid diagnosis and elimination of unnecessary interventions and chronic condition development in the future.

The Carter report stated: “If benchmarks for pathology are unlikely to be achieved (by the deadline of April 2017), trusts should have agreed plans for consolidation and outsourcing to other providers by January 2017.”

"Our report recognises frustrations that greater productivity gains have not yet been achieved."

The latest report countered the imposition of strict timelines, stating that consolidations are unsuitable for within-laboratory efficiency and improvement drives.

The MindMetre review advocated a mandatory pathway for laboratory productivity improvement, while considering the NHS fundamental of delivering efficiency savings in the current policy environment.

It also suggested the re-appraisal of high value offered by pathology services to adjudge their position in the NHS service funding priorities.

Mind Metre managing director Paul Lindsell said: “A knee-jerk push to consolidate pathology labs is not an easy universal panacea. There is evidently significant headroom for efficiency and productivity gains in pathology workflows and emerging technology.

“Our report recognises frustrations that greater productivity gains have not yet been achieved.

“However, we also suggest that the through-the-line benefits pathology services offer mean it would be a mistake to potentially squeeze such resources in the NHS. In fact, there may be a rationale to put greater resources into pathology services, so long as they are strictly pegged to productivity improvements.”

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena